15xxGCC: PHASE II TRIAL OF THE EP4 RECEPTOR ANTAGONIST, AAT-007 (RQ-07; CJ-023,423) IN ADVANCED SOLID TUMORS
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2016
At a glance
- Drugs Grapiprant (Primary) ; Gemcitabine
- Indications Advanced breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- 19 May 2016 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 19 May 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 19 May 2016 Planned initiation date changed from 1 Dec 2015 to 1 Jan 2017.